Liver shunt may boost outcomes in liver cancer patients on immunotherapy
NCT ID NCT07365930
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with advanced liver cancer who are starting a combination of two drugs (atezolizumab and bevacizumab). It will test if adding a procedure called TIPS (which places a small tube in the liver to improve blood flow) can help keep the liver working better for longer. The study will follow 350 participants to compare liver function, survival, and quality of life between those who get TIPS and those who do not.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital of Düsseldorf
RECRUITINGDüsseldorf, North Rhine-Westphalia, 40225, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success
- Can a diabetes drug help fight liver cancer? a trial puts it to the test
- Can a triple therapy shrink untreatable liver tumors?